Vera Therapeutics, INC Schedule 13G passive stakes

Kynam Capital Management, LP, along with its affiliates, has reported beneficial ownership of 4.01% of Vera Therapeutics, Inc.'s Class A common stock as of June 30, 2026.

State Street Corporation has disclosed beneficial ownership of 5.8% of Vera Therapeutics Inc. common stock as of June 30, 2026.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, has disclosed a 1.7% beneficial ownership stake in Vera Therapeutics, Inc.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Vera Therapeutics Inc. following an internal realignment.

T. Rowe Price Associates, Inc. has disclosed an increased beneficial ownership of 7.7% in Vera Therapeutics Inc. common stock.

FMR LLC and Abigail P. Johnson have disclosed a 4.1% beneficial ownership stake in Vera Therapeutics Inc.'s Class A Common Stock as of December 31, 2025.

The Vanguard Group reported a 5.03% beneficial ownership stake in Vera Therapeutics Inc., holding 3,570,401 common shares as of December 31, 2025.

T. Rowe Price Associates, Inc. has increased its beneficial ownership in Vera Therapeutics Inc. to 5.7% of common stock as of September 30, 2025.

Kynam Capital Management, LP, along with its affiliates, has disclosed a 5.37% beneficial ownership stake in Vera Therapeutics, Inc.'s Class A common stock.

Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., and James E. Flynn have jointly disclosed a passive beneficial ownership of 5.25% in Vera Therapeutics, Inc., totaling 3,348,117 shares of common stock.

Avoro Capital Advisors LLC and its controlling person, Behzad Aghazadeh, have filed an amended Schedule 13G, reporting a continued beneficial ownership of 8.9% in Vera Therapeutics, Inc.'s Class A Common Stock as of December 31, 2024.